NCT07640737: AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
- State
- Not started
- Phase
- Phase 2
- People
- 30 planned
- Started
- 30 Jun 2026
- Primary completion
- 30 Dec 2028
- Arms
- Phase 2 single agent study AUR103 calcium administered as 200 mg or 300 mg twice daily.
- Results
- None posted
- 11 Jun 2026: Trial registered